Obesity Clinical Trial Landscape Broadens With 100+ Novel Therapies, Says DelveInsight

Major companies active in the obesity space include Pfizer, Biolingus, Regor Pharmaceuticals, Zealand Pharma, Sirnaomics, Innovent Biologics, PegBio, NodThera Limited, Sciwind Biosciences, Boehringer Ingelheim, Clearmind Medicine, Sparrow Pharmaceuticals, Genexine, TransThera, Fractyl Health, Shionogi, among others.
As per DelveInsight's latest evaluation, more than 80 prominent organizations worldwide are currently involved in the development of over 100 therapeutic candidates aimed at obesity management.

DelveInsight's "Obesity Pipeline Insight" report delivers a comprehensive analysis of ongoing clinical trials, therapeutic approaches, mechanisms of action, administration routes, and recent advancements in obesity drug development. The study outlines the existing clinical development ecosystem and future growth opportunities within the obesity market. It features detailed profiles of pipeline candidates across both clinical and preclinical stages and evaluates therapies based on product category, development phase, delivery method, and molecular class. Additionally, the report sheds light on discontinued and inactive pipeline assets in the obesity domain.

The Obesity Pipeline Report by DelveInsight presents an extensive commercial and clinical evaluation of drug candidates spanning from early discovery to commercialization. Each therapy profile includes insights into its mechanism of action, clinical trial status, regulatory milestones such as NDA approvals, and development activities including platform technologies, partnerships, mergers and acquisitions, funding events, and special regulatory designations. This in-depth coverage equips stakeholders with actionable intelligence on emerging opportunities in obesity therapeutics.

Stay informed with the newest updates! Access DelveInsight's all-encompassing Obesity Pipeline Report to discover innovative therapies, leading obesity-focused companies, and the evolving landscape of obesity treatments @ [https://www.delveinsight.com/report-store/obesity-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Key Highlights From the Obesity Pipeline Report

* January 2026: Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the novel TOGETHER-PsA open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in adults with active psoriatic arthritis (PsA) and obesity or overweight with at least one weight-related condition. At 36 weeks, treatment with concomitant Taltz and Zepbound met the primary and all key secondary endpoints for superiority to Taltz monotherapy. TOGETHER-PsA is the first controlled study to evaluate an incretin therapy used with a PsA biologic. An estimated 65% of adults with PsA in the U.S. also have obesity (BMI greater than or equal to 30 kg/m) or overweight (BMI 27-29.9 kg/m) with at least one additional weight-related comorbidity,1 highlighting a need for integrated treatment approaches that address the full burden of their diseases.
* January 2026, Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More. Hanmi is accelerating its global market entry with efpeglenatide, Korea's first domestically developed GLP-1 class obesity and metabolic disease treatment.
* January 2026: Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP receptor agonist being developed for the treatment of obesity. The study found that once-weekly subcutaneous injections of CT-388 (titrated up to 24 mg) resulted in significant and clinically meaningful placebo-adjusted weight loss of 22.5% (efficacy estimand) without reaching a weight loss plateau at 48 weeks. A clear dose-response relationship on the weight loss was observed. For the treatment-regimen estimand, the placebo-adjusted weight loss achieved with CT-388 was 18.3% (p-value < 0.001). At week 48 for the 24 mg dose, 95.7% of CT-388 treated participants achieved a weight loss of greater than or equal to 5%, 87% achieved greater than or equal to 10%, 47.8% achieved greater than or equal to 20%, and 26.1% achieved greater than or equal to 30%. 73% of participants who were pre-diabetic at baseline and treated with CT-388 at 24 mg achieved normal blood glucose levels at week 48 compared to 7.5% in the placebo group.
* January 2026: Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye") a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today presented a poster titled "Investigating the Efficacy of Nimacimab Alone or in Combination with Tirzepatide, and as a Maintenance Therapy Post Tirzepatide Discontinuation in a Diet-Induced Obesity (DIO) Mouse Model" at Keystone's conference, Obesity Therapeutics: Unlocking Benefits and Minimizing Side Effects.
* January 2026, Nxera Pharma Co. Ltd ("Nxera" or "the Company; TSE 4565) today announces the formation of a Metabolic Advisory Council comprising world-leading industry experts to provide scientific, clinical, and strategic guidance as Nxera advances its rapidly growing pipeline of next-generation therapies targeting obesity and metabolic disorders.
* December 2025: Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced positive interim data from the lowest therapeutic cohort of the ongoing first-in-human INLIGHT trial evaluating WVE-007, an investigational INHBE GalNAc-siRNA using Wave's proprietary SpiNA design, for the treatment of obesity. In this interim assessment, a single 240 mg dose of WVE-007 led to an improvement in body composition characterized by reductions in total and visceral fat mass at three months and an increase in lean mass. There was also a favorable safety profile as well as durable reductions in serum Activin E that support potential once or twice-yearly dosing.
* November 2025: Mangoceuticals, Inc. (NASDAQ: MGRX), a telemedicine-driven health and wellness company operating under MangoRx and PeachesRx, announced the launch of MangoRx Direct and PeachesRx Direct. These programs offer direct patient access to Zepbound Registered (tirzepatide) by Eli Lilly and Wegovy Registered (semaglutide) from Novo Nordisk.
* November 2025: Wave Life Sciences Ltd. (Nasdaq: WVE) reported the presentation of preclinical findings for WVE-007, a GalNAc-siRNA candidate for obesity, at ObesityWeek Registered in Atlanta. The data highlight the therapeutic's potential in metabolic disease management.
* August 2025: Teva Pharmaceuticals' U.S. subsidiary announced FDA approval and commercial launch of a generic version of Saxenda Registered (liraglutide injection).
* June 2025: Regeneron Pharmaceuticals disclosed a strategic licensing agreement with Hansoh Pharmaceuticals to obtain ex-China rights for HS-20094, a Phase III dual GLP-1/GIP receptor agonist. The therapy has demonstrated encouraging efficacy and safety in more than 1,000 patients and is administered as a once-weekly subcutaneous injection.
* May 2025: Novo Nordisk confirmed FDA acceptance of its NDA for a once-daily oral 25 mg formulation of Wegovy Registered (semaglutide) for chronic weight management and cardiovascular risk reduction. If approved, it would become the first oral GLP-1 therapy for obesity.
* February 2025: Carmot Therapeutics initiated a Phase II randomized, placebo-controlled study evaluating weekly subcutaneous CT-388 in overweight or obese patients with type 2 diabetes.
* February 2025: Eli Lilly and Company launched a long-term clinical study comparing retatrutide with tirzepatide in adults living with obesity.
* February 2025: Zomagen Biosciences commenced a safety study of VTX3232, administered alone or alongside semaglutide, in approximately 160 obesity patients.
* February 2025: Novo Nordisk began a multi-year study assessing the weight-loss efficacy of CagriSema compared to placebo in individuals with obesity.
* February 2025: Boehringer Ingelheim initiated a Phase III trial evaluating survodutide (BI 456906) in overweight and obese patients, with weekly injections administered over approximately 18 months.
* February 2025: Rhythm Pharmaceuticals advanced a Phase III program investigating setmelanotide in patients with rare genetic obesity syndromes affecting the MC4 receptor pathway.
* DelveInsight's analysis highlights a highly competitive obesity pipeline, with more than 80 active companies collectively developing over 100 therapeutic candidates.
* Leading organizations in the obesity treatment landscape include Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others.
* Prominent obesity drug candidates include APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and additional emerging therapies.

Discover how the Obesity treatment paradigm is evolving. Access DelveInsight's in-depth Obesity Pipeline Analysis for a closer look at promising breakthroughs @ [https://www.delveinsight.com/sample-request/obesity-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Notable Emerging Obesity Therapies

Survodutide - Zealand Pharma Survodutide (BI 456906) is a once-weekly dual glucagon/GLP-1 receptor agonist designed to enhance weight loss efficacy through dual hormonal activation. The therapy is under development for obesity and NASH, with Boehringer Ingelheim conducting three global Phase III trials.

Ecnoglutide - Sciwind Biosciences Ecnoglutide (XW003) is a next-generation, long-acting GLP-1 analog featuring biased cAMP signaling. Optimized for weekly dosing and cost-effective production, it is currently undergoing Phase III evaluation for obesity treatment.

CT-868 - Carmot Therapeutics CT-868 is a dual GLP-1/GIP receptor modulator designed to improve tolerability while delivering robust weight reduction and glycemic control. The therapy is administered once daily and is presently in Phase II clinical development.

DD01 - D&D Pharmatech DD01 is a proprietary GLP-1/glucagon dual agonist with an extended half-life. Preclinical data demonstrate sustained weight loss, liver fat reduction, and metabolic improvements. The therapy is currently being evaluated in Phase I trials.

Insights Covered in the Obesity Pipeline Report

* Comprehensive profiling of companies developing obesity therapies and their respective pipelines
* Segmentation of candidates across early, mid, and late development stages
* Evaluation of active and discontinued obesity programs
* Detailed analysis by development stage, route of administration, molecular class, and mechanism of action
* In-depth review of partnerships, licensing deals, funding activities, and strategic collaborations shaping the obesity market

Get a detailed analysis of the latest innovations in the Obesity pipeline. Explore DelveInsight's expert-driven report today! @ [https://www.delveinsight.com/report-store/obesity-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Obesity Route of Administration Covered

* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical

Obesity Molecule Types Analyzed

* Recombinant fusion proteins
* Small molecules
* Monoclonal antibodies
* Peptides
* Polymers
* Gene therapies

Download DelveInsight's latest report to gain strategic insights into upcoming Obesity Therapies and key Obesity Developments @ [https://www.delveinsight.com/sample-request/obesity-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Scope of the Obesity Pipeline Report

* Geographical Coverage: Global
* Key Companies: Pfizer, Biolingus, Regor Pharmaceuticals, Zealand Pharma, Sirnaomics, Innovent Biologics, PegBio, NodThera Limited, Sciwind Biosciences, Boehringer Ingelheim, Clearmind Medicine, Sparrow Pharmaceuticals, Genexine, TransThera, Fractyl Health, Shionogi, and others.
* Key Therapies: APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide
* Assessment Parameters: Product type, clinical stage, monotherapy vs. combination approaches

Which companies are leading the race in Obesity drug development? Find out in DelveInsight's exclusive Obesity Pipeline Report - access it now! @ Obesity Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/obesity-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Content

* Introduction
* Executive Summary
* Obesity Overview
* Obesity Pipeline Therapeutics
* Obesity Therapeutic Assessment
* Late Stage Products (Phase III)
* Survodutide: Zealand Pharma
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* CT-868: Carmot Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* DD01: D&D Pharmatech
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Obesity Products
* Obesity Key Companies
* Obesity Key Products
* Obesity Unmet Needs
* Obesity Market Drivers
* Obesity Market Barriers
* Obesity Future Perspectives and Conclusion
* Obesity Analyst Views
* Obesity Key Companies
* Appendix

About DelveInsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=obesity-clinical-trial-landscape-broadens-with-100-novel-therapies-says-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.